These are the data of a clinical trial in Schizophrenia (a subset of the dataset Schizo_Bin, study \(1\) where the patients were administered \(10\) mg. of haloperidol or \(8\) mg. of risperidone). A total of \(454\) patients were treated by \(117\) investigators (psychiatrists). Patients' schizophrenia symptoms at baseline and at the end of the study (after \(8\) weeks) were measured using the PANSS and BPRS.
The variables BPRS_Bin and PANSS_Bin are binary outcomes that indicate whether clinically meaningful change had occurred (1 = a reduction of \(20\)% or higher in the PANSS/BPRS scores at the last measurement compared to baseline; 0 = no such reduction; Leucht et al., 2005; Kay et al., 1988).
data(Schizo_Bin)A data.frame with \(454\) observations on \(5\) variables.
IdThe patient ID.
InvestIThe ID of the investigator (psychiatrist) who treated the patient.
TreatThe treatment indicator, coded as \(-1\) = control treatment (10 mg. haloperidol) and \(1\) = experimental treatment (8 mg. risperidone).
PANSS_BinThe dichotomized change in the PANSS score (1 = a reduction of \(20\)% or more in the PANSS score, 0=otherwise)
BPRS_BinThe dichotomized change in the BPRS score (1 = a reduction of \(20\)% or more in the BPRS score, 0=otherwise)
CGI_BinThe sichtomized change in the CGI score, coded as \(1\) = a change of more than \(3\) points on the original scale (score at the end of the treatment relative to score at the beginning of the treatment), \(0\) = otherwise.
Kay, S.R., Opler, L.A., & Lindenmayer, J.P. (1988). Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatric Research, 23, 99-110.
Leucht, S., et al. (2005). Clinical implications of Brief Psychiatric Rating Scale scores. The British Journal of Psychiarty, 187, 366-371.